HER2+ Breast Cancer | Specialty

The Role of Fulvestrant in HR+ Breast Cancer

February 17th 2018

Abemaciclib for HR-Positive Metastatic Breast Cancer

February 17th 2018

Quality of Life for Women with HR-Positive Breast Cancer

February 17th 2018

MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

February 17th 2018

Expert Highlights Evolving Options in HER2+ Breast Cancer

February 15th 2018

Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.

Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer

February 14th 2018

Kimberly L. Blackwell, MD, discusses novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.

Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer

February 14th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.

Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer

February 7th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses ongoing trials for patients with HER2-positive breast cancer.

Dr. Blackwell Discusses Tucatinib in HER2+ Breast Cancer

February 3rd 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the role of tucatinib (ONT-380) for patients with HER2-positive breast cancer.

Dr. Traina on Treatment Considerations for HER2+ Breast Cancer

February 3rd 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.

Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer

February 2nd 2018

The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.

Priority Reviews in Ovarian Cancer, Prostate Cancer, NSCLC, and More

February 2nd 2018

Treatment Landscape for HER2-Positive Breast Cancer

February 2nd 2018

Breast Cancer: Extended Adjuvant Therapy and Cost Factors

February 2nd 2018

Use of Neratinib in HER2-Positive Breast Cancer

February 2nd 2018

Chemotherapy With Adjuvant Therapy in Breast Cancer

February 2nd 2018

Adjuvant Therapy Data for HER2-Positive Breast Cancer

February 2nd 2018

Breast Cancer: Factors to Consider for Adjuvant Therapy

February 2nd 2018

Treating Patients with HER2+ Breast Cancer: Impact of Cost

February 2nd 2018

Role for Neratinib Following Adjuvant Dual-Targeted HER2 Therapy

February 2nd 2018